Randomized Phase 2 Trial of Sunitinib or Cediranib in Alveolar Soft Part Sarcoma.
James NguyenNaoko TakebeShivaani KummarAlbiruni Abdul RazakSant P ChawlaSuzanne GeorgeShreyaskumar R PatelMary Louise KeohanSujana MovvaGeraldine O'Sullivan CoyneKhanh T DoLamin JawaraBrooke AugustineSeth M SteinbergLaura KuhlmannSusan Percy IvyJames H DoroshowHelen X ChenPublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2022)
The study did not meet its endpoints for ORR. Although both TKIs provided clinical benefit, the outcomes may have been attenuated in patients who had progressed ≤6 months before enrollment, potentially accounting for the low response rates.